Revised: 7 July 2026
Medicines
Product/Application Search
- Product search: Explanation of regulatory status
In the Product search result table, the ‘Status’ column shows the regulatory status of the medicinal product. The list below explains the different status meanings. The ‘Approval date’ is the date that the medicinal product was first approved for use in New Zealand. The ‘Notification date’ is the date of the most recent regulatory status change (eg, from Consent given to Not available).
Regulatory status has the following meanings:
- Approval lapsed
- where consent has lapsed due to a product being not available and there being no regulatory activity on it for more than five years, or where provisional consent has expired or where a sponsor has advised in writing that the product is no longer distributed in New Zealand.
- Clinical trial
- where a product is for clinical trial only.
- Consent given
- where a product has been granted consent to market in New Zealand under section 20 of the Medicines Act 1981 and is actively marketed or is available upon request.
- Consent refused
- where a product has been refused consent under section 20 of the Medicines Act 1981.
- Consent Revoked
- where consent has been revoked under section 35(1)(a) of the Medicines Act 1981.
- Excluded product
- where a product is declared by regulation 58A of the Medicines Regulations 1984 not to be a medicine or related product.
- Export only
- where a product is for export only and is not to be marketed in New Zealand.
- File closed
- where a product has been rationalized. This may mean that some of the previous product history is on another file.
- Never approved
- where an application is still pending but it is no longer possible to contact the applicant to either obtain additional information or confirmation of withdrawal.
- NMA withdrawn
- where the applicant has advised in writing that they no longer want to proceed with the application.
- Not available
- where a product has been granted consent but the company has advised in writing that they do not supply the product upon request or actively market it.
- Pending
- where an NMA is still under assessment.
- Provisional consent
- where provisional consent has been granted under section 23 of the Medicines Act 1981.
Notes:
- If approval has lapsed consent to the distribution of a new medicine needs to be granted before the product can be reintroduced onto the New Zealand market.
- If a product is not available, a CMN is required to reintroduce it into the market or a justification submitted in writing demonstrating that the regulatory file is current, prior to the registration situation being updated. CMNs or justifications must be submitted 90 days prior to commencing distribution.
- For prescription or restricted medicines a CMN must be submitted for evaluation that includes a revised data sheet to demonstrate that all required updates have been included. Self-assessable change notifications will not be accepted.
- Application search: Explanation of application status
The application status used for NMAs and CMNs is the same. Once an application has been received and an invoice issued it will appear in the Product/Application search. While the invoice is awaiting payment the status column will indicate 'awaiting payment'.
Once payment has been received the application is assigned to an evaluator for initial evaluation. During this period the status column of the application in the application search will indicate 'initial evaluation'. The outcome of the initial evaluation may result in a Request for Information (RFI).
When an RFI is issued the status of the application will indicate 'information requested'.
When the response to the RFI is under evaluation the status of the application will indicate 'additional evaluation'.
Once evaluation of a CMN has been completed, and consent to sell and supply a changed medicine under section 24(3) of the Medicines Act 1981 has been made, the application status will indicate 'granted' with the date of consent alongside.
If any concerns with a CMN that have not been resolved within 90 days of receipt of payment, the application will be referred under section 24(5)(b) of the Medicines Act 1981 to undergo evaluation according to the NMA timeframes. This referral of the CMN under section 24(5)(b) will occur regardless of whether the resolution of issues identified resides with Medsafe or the applicant.
Once the evaluation of a NMA has been completed the product will either been forwarded for the gazettal process or referred for the next MAAC meeting, the status of the application will indicate 'evaluation complete' or 'referral to MAAC'. Once the product has been gazetted, the status will read 'granted' with the date of gazettal underneath.
When applications accepted for priority assessment are allocated to an evaluator, it is assigned as their next piece of work to be completed. The evaluation of responses to RFIs for priority assessments are treated the same way. The time taken to complete the evaluation depends on the complexity of the dossier, the quality of the dossier, and the total number of priority assessments under evaluation at any one time.
Medsafe's Evaluation Policy for Priority and Abbreviated Assessments
Evaluation Queue Information
Please note that the progress of applications from the time they are assigned to an evaluator will depend on a number of factors, such as the number and complexity of applications with a common application date. Please remember that the workload of individual evaluators does vary so it is possible that the evaluation reports may not be reviewed and issued in chronological order.
Although the timelines referred to above indicate Medsafe's intended timeframes, occasionally an application may exceed the target time due to its complexity, and/or need to solicit independent expert advice.
Medsafe requests that companies do not seek more specific information concerning queue status as researching these queries takes evaluators away from their technical assessments.
Note: While the status of an application may show ‘Evaluation complete’, ‘Granted’ or ‘Information requested’, it may be 1-2 days before an applicant receives formal notification (and associated documentation) by email. Applicants should take this into account before contacting Medsafe to request the formal notification.
15 records found
Approval date | Notification date | ||||
|---|---|---|---|---|---|
| 3M Avagard 8615 Pre-Surgical Skin Preparation with Povidone Iodine, Topical solution 1% w/w (General sale) | Iodine | 3M New Zealand Ltd | Approval lapsed | 18/07/2002 | 16/03/2009 |
| Addaven, Solution for infusion . (General sale) (Previously known as: Addamel N) | Chromium trichloride + Copper chloride + Ferric chloride + Manganese chloride + Potassium iodide + Sodium fluoride + Sodium molybdate + Sodium selenite + Zinc chloride | Fresenius Kabi New Zealand Limited | Consent given | 17/10/1991 | |
| Blackmores Iodine 150 mcg, Film coated tablet 150 mcg (General sale) | Potassium iodide | Blackmores (NZ) Ltd | Approval lapsed | 9/08/2012 | 27/08/2020 |
| Elevit with Iodine, Film coated tablet . (Pharmacy only) | Ascorbic acid + Biotin + Calcium hydrogen phosphate + Colecalciferol + Copper + Cyanocobalamin + D-alpha Tocoferol + Ferrous fumarate + Folic acid + Magnesium oxide + Magnesium phosphate + Manganese sulfate + Nicotinamide + Pantothenic acid + Potassium iodide + Pyridoxine + Riboflavin + Thiamine + Zinc sulfate | Bayer New Zealand Limited | Approval lapsed | 13/05/2010 | 8/11/2024 |
| Elevit, Film coated tablet Bayer UI 1613794 (Pharmacy only) | Ascorbic acid + Biotin + Calcium hydrogen phosphate + Colecalciferol + Copper + Cyanocobalamin + dl-Alpha tocopherol + Ferrous bisglycinate + Folic acid + Levomefolic acid + Magnesium oxide + Manganese sulfate + Nicotinamide + Pantothenic acid + Potassium iodide + Pyridoxine + Riboflavin + Sodium selenite + Thiamine + Zinc citrate | Bayer New Zealand Limited | Consent given | 26/01/2023 | |
| Elevit, Film coated tablet New formulation (Pharmacy only) | Ascorbic acid + Biotin + Calcium hydrogen phosphate + Colecalciferol + Copper + Cyanocobalamin + dl-Alpha tocopherol + Ferrous fumarate + Folic acid + Magnesium oxide + Manganese sulfate + Nicotinamide + Pantothenic acid + Potassium iodide + Pyridoxine + Riboflavin + Sodium selenite + Thiamine + Zinc citrate | Bayer New Zealand Limited | Consent given | 14/11/2019 | |
| Elevit, Film coated tablet Vitamin D 5 microgram (Pharmacy only) | Ascorbic acid + Biotin + Calcium hydrogen phosphate + Colecalciferol + Copper + Cyanocobalamin + dl-Alpha tocopherol + Ferrous fumarate + Folic acid + Magnesium oxide + Manganese sulfate + Nicotinamide + Pantothenic acid + Potassium iodide + Pyridoxine + Riboflavin + Sodium selenite + Thiamine + Zinc citrate | Bayer New Zealand Limited | Consent given | 25/03/2021 | 3/02/2022 |
| Iodine Strong, Topical solution 10% /6% w/v (Pharmacy only) | Iodine + Potassium iodide | PSM Healthcare Ltd trading as API Consumer Brands | Approval lapsed | 31/12/1969 | 2/08/1996 |
| Microshield PVP Povidone-Iodine Surgical Handwash, Topical solution 75 mg/mL (General sale) (Previously known as: Microshield PVP) | Povidone-iodine | Schulke New Zealand Limited | Consent given | 19/07/2018 | |
| Microshield* PVP-S, Topical solution 10% w/v (General sale) | Povidone-iodine | Johnson & Johnson (New Zealand) Limited | Approval lapsed | 5/11/1992 | 17/05/2004 |
| Myadec, Capsule . (General sale) | Ascorbic acid + Calcium hydrogen phosphate + Colecalciferol + Copper + Cyanocobalamin + dl-Alpha tocopherol + Ferrous sulfate + Magnesium stearate + Magnesium sulfate + Manganese sulfate + Nicotinamide + Potassium iodide + Potassium sulfate + Pyridoxine + Riboflavin + Thiamine + Zinc sulfate | Pharmabroker Sales Ltd | Approval lapsed | 31/12/1969 | 2/07/2001 |
| Natalis, Film coated tablet . (Pharmacy only) | Ascorbic acid + Biotin + Calcium carbonate + Calcium hydrogen phosphate + Colecalciferol + Copper + Cyanocobalamin + dl-Alpha tocopherol + Ferrous fumarate + Folic acid + Magnesium oxide + Magnesium stearate + Manganese sulfate + Nicotinamide + Pantothenic acid + Potassium iodide + Pyridoxine + Riboflavin + Sodium selenate + Thiamine + Zinc citrate | Arrotex Pharmaceuticals (NZ) Limited | Consent given | 29/01/2026 | |
| Ped-el sterile, Solution for injection see composition (General sale) | Calcium chloride + Copper chloride + Ferric chloride + Magnesium chloride + Manganese chloride + Phosphoric acid + Potassium iodide + Sodium fluoride + Zinc chloride | Pfizer New Zealand Limited | Approval lapsed | 21/06/1990 | 28/11/2012 |
| Peditrace, Solution for infusion . (General sale) | Copper chloride + Manganese chloride + Potassium iodide + Sodium fluoride + Sodium selenite + Zinc chloride | Fresenius Kabi New Zealand Limited | Approval lapsed | 21/06/1995 | 5/08/2021 |
| Rawleigh's Ru-Mex-Ol, Unknown Unknown (General sale) | Potassium iodide + Rheum palmatum + Salicylic acid + Sodium benzoate | Rawleighs (2004) Ltd | Approval lapsed | 31/12/1969 |
